DURECT Corporation to highlight new data on Larsucosterol for alcohol-associated hepatitis at The Liver Meeting 2024
DURECT Corporation a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce… read more.
